ライフサイエンスコーパス: mitomycin

1 acil (1000 mg/m2 on days 1-4 and 29-32) plus mitomycin (10 mg/m2 on days 1 and 29) and radiotherapy (

2 ned to one of four groups, to receive either mitomycin (12 mg/m(2) on day 1) or cisplatin (60 mg/m(2)

3 ve six instillations of once-weekly UGN-101 (mitomycin 4 mg per mL; dosed according to volume of pati

4 py [n=136]); to ASC plus MVP (four cycles of mitomycin 6 mg/m2, vinblastine 6 mg/m2, and cisplatin 50

5 of DHS5373 revealed continued production of mitomycin A and mitomycin C in addition to the accumulat

6 of the 7-OMe group that is characteristic of mitomycins A and B and demonstrates the prerequisite of

7 esis of the quinone methoxy group present in mitomycins A and B.

8 Production of mitomycins A and C or mitomycin B was selectively restor

9 not involved directly in the biosynthesis of mitomycins A and C.

10 had been deleted failed to produce the three mitomycins (A, B, and C) that are typically isolated fro

11 n C in addition to the accumulation of a new mitomycin analog, 9-epi-mitomycin C.

12 Mitomycin and platinum-based chemotherapeutic agents wer

13 e survival rate from concurrent fluorouracil/mitomycin and radiation is only approximately 65%.

14 l comparing treatment with fluorouracil plus mitomycin and radiotherapy vs treatment with fluorouraci

15 I Randomized Study of 5-Fluorouracil (5-FU), Mitomycin, and Radiotherapy Versus 5-Fluorouracil, Cispl

16 Production of mitomycins A and C or mitomycin B was selectively restored upon supplementing

17 igned to 1 of 2 intervention groups: (1) the mitomycin-based group (n = 341), who received fluorourac

18 5% confidence interval [CI], 53%-67%) in the mitomycin-based group and 54% (95% CI, 46%-60%) in the c

19 rvival rate was 75% (95% CI, 67%-81%) in the mitomycin-based group and 70% (95% CI, 63%-76%) in the c

20 te of colostomy was significantly better for mitomycin-based than cisplatin-based treatment (10% vs 1

21 improve disease-free-survival compared with mitomycin-based therapy, but cisplatin-based therapy res

22 higher rate of colostomy (P = .03) than was mitomycin-based therapy.

23 antly higher rate of colostomy compared with mitomycin-based therapy.

24 Severe hematologic toxicity was worse with mitomycin-based treatment (P < .001).

25 and 15% (95% CI, 10%-20%), respectively, for mitomycin-based treatment and 33% (95% CI, 27%-40%) and

26 to methyltransferases, is located within the mitomycin biosynthetic gene cluster.

27 An inframe deletion in mitN of the mitomycin biosynthetic pathway was generated in Streptom

28 In order to lower IOP, trabeculectomy with mitomycin C (0.2 mg/cc) was performed under general anes

29 ldt glaucoma implant) or trabeculectomy with mitomycin C (0.4 mg/ml for 2 minutes).

30 ant) and 105 patients to trabeculectomy with mitomycin C (0.4 mg/mL for 4 minutes).

31 ions 1 to 5 and 16 to 20 of radiotherapy and mitomycin C (12 mg per square meter) on day 1.

32 Trabeculectomy with mitomycin C (8 eyes) and trabeculotomy (8 eyes) had 25%

33 ldt glaucoma implant) or trabeculectomy with mitomycin C ([MMC]; 0.4 mg/mL for 4 minutes).

34 anesulfonate (generating alkylation damage), mitomycin C (generating interstrand cross-links), or pot

35 eculotomy with trabeculectomy augmented with mitomycin C (Group II).

36 The cancer chemotherapeutic agent mitomycin C (MC) alkylates and cross-links DNA monofunct

37 Survival after treatment with UV, mitomycin C (MC) or methyl methanesulfonate (MMS), as we

38 The anticancer drugs, mitomycin C (MIC(50) = 0.25 mug/ml) and mithramycin A (M

39 ldt glaucoma implant) or trabeculectomy with mitomycin C (MMC 0.4 mg/mL for 4 minutes).

40 ) Baerveldt implant) and trabeculectomy with mitomycin C (MMC) (0.4 mg/ml for 4 minutes) in patients

41 , reduced engraftment potential of HSPC, and Mitomycin C (MMC) -sensitive hematopoiesis), were absent

42 r subconjunctival injection of a solution of mitomycin C (MMC) and 1% preservative-free lidocaine (as

43 ion stress, including the crosslinking agent mitomycin C (MMC) and the replication inhibitor hydroxyu

44 Ten eyes received mitomycin C (MMC) and triamcinolone.

45 Experience with mitomycin C (MMC) application during corneal surface abl

46 excimer lasers and standardized surgical and mitomycin C (MMC) application protocols.

47 han control cells to DNA cross-linking agent mitomycin C (MMC) but were not hypersensitive to UV irra

48 show that the FDA-approved anti-cancer drug mitomycin C (MMC) eradicates persister cells through a g

49 he FA-characteristic growth inhibition after mitomycin C (MMC) exposure.

50 al setting who underwent trabeculectomy with mitomycin C (MMC) for uncontrolled elevated intraocular

51 Antifibrotics were used in 400 cases (93%): mitomycin C (MMC) in 271 (63%), 5-fluorouracil (5-FU) in

52 of tube-shunt surgery to trabeculectomy with mitomycin C (MMC) in eyes with previous cataract and/or

53 Mitomycin C (MMC) is a commonly used and extensively stu

54 Trabeculectomy with mitomycin C (MMC) is a major treatment option, although

55 A single application of Mitomycin C (MMC) is used clinically in ophthalmology to

56 in one eye followed by treatment with either mitomycin C (MMC) or vehicle.

57 ion of Blm in Rad54(-/-) cells rescued their mitomycin C (MMC) sensitivity, and decreased both the le

58 reased sensitivity to the DNA damaging agent mitomycin C (MMC) that correlates with delayed repair of

59 es a rapid liver repopulation protocol using mitomycin C (MMC) to block proliferation of rat hepatocy

60 mologists rely on accurate concentrations of mitomycin C (MMC) to prevent scarring with trabeculectom

61 interno gelatin microstent implantation with mitomycin C (MMC) versus trabeculectomy with MMC.

62 nonpenetrating deep sclerectomy (NPDS) with mitomycin C (MMC) versus XEN(R) gel stent with MMC.

63 Intraoperative mitomycin C (MMC) was associated with reduced failure fo

64 hanesulphonate (MMS), camptothecin (CPT) and mitomycin C (MMC), agents that hinder the progression of

65 in greatly increased cellular sensitivity to mitomycin C (MMC), and in increased levels of spontaneou

66 n human cells results in hypersensitivity to mitomycin C (MMC), but not to IR.

67 uivocal sensitivity to crosslinkers, such as mitomycin C (MMC), we find that they are largely resista

68 hocytes displayed higher levels of basal and mitomycin C (MMC)-induced chromosomal abnormalities.

69 ed DNA damage, but is deficient in repair of mitomycin C (MMC)-induced DNA damage.

70 Moreover, repair of mitomycin C (MMC)-induced DSBs and sister chromatid exch

71 ing salinity and the DNA cross-linking agent mitomycin C (MMC).

72 e DNA interstrand crosslinks (ICLs), such as mitomycin C (MMC).

73 s in response to the DNA cross-linking agent mitomycin C (MMC).

74 , or the DNA interstrand cross-linking agent mitomycin C (MMC).

75 atectomy (PRK) procedure with application of mitomycin C (MMC).

76 concentration of the DNA cross-linking agent mitomycin C (MMC).

77 e radial formation by the ICL-inducing agent mitomycin C (MMC).

78 ssociated with European-derived race; use of mitomycin C (MMC); higher concentrations of MMC, when us

79 RECQL5, but not BLM, conferred resistance to mitomycin C (MMC, an interstrand crosslinker) and campto

80 ldt glaucoma implant) or trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes).

81 the re-evaluation of the action mechanism of Mitomycin C (MtoC), a widely used antitumor chemotherape

82 Mitomycin C 0.02% was used after the PRK to prevent haze

83 mycin C analogue which is twice as potent as mitomycin C against the prostate cancer cells.

84 red with conjunctival or limbal autograft or mitomycin C alone.

85 l synthesis and rapid discovery of MTSB-6, a mitomycin C analogue which is twice as potent as mitomyc

86 rently being investigated as alternatives to mitomycin C and 5-fluorouracil to reduce inflammation an

87 ckout cells display increased sensitivity to mitomycin C and a delay in FANCD2 foci formation compare

88 wering, stem fasciation, hypersensitivity to mitomycin C and amino acid analogs, hyposensitivity to t

89 onic exposure to genotoxic molecules such as mitomycin C and antibiotics of the fluoroquinolone famil

90 ponse to DNA damage caused by diepoxybutane, mitomycin C and bleomycin.

91 Depletion of SLX4 causes sensitivity to mitomycin C and camptothecin and reduces the efficiency

92 s induced by chemotherapeutic agents such as mitomycin C and cisplatin.

93 mong other adjuvants, there is evidence that mitomycin C and conjunctival or limbal autografts reduce

94 e levels induced by two DNA-damaging agents, mitomycin C and daunorubicin, and two apoptosis-inducing

95 )-guanines, similar to cross-links formed by mitomycin C and enals.

96 by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Deltaex11/Y3308

97 ned their characteristic hypersensitivity to mitomycin C and exhibited high levels of chromosomal ins

98 my groups were treated intraoperatively with mitomycin C and followed postoperatively for 2 years.

99 Although both mitomycin C and ionizing radiation induced FANCD2 monoub

100 ity upon exposure to the DNA-damaging agents mitomycin C and Irofulven, but not etoposide and camptot

101 but they are not sensitive to treatment with mitomycin C and methyl methanesulfonate.

102 The most potent FDA-approved drugs (mitomycin C and mithramycin A) and a promising natural p

103 rsensitivity to the DNA crosslinking agents, mitomycin C and olaparib, as proxies for functional DNA

104 ients treated with concurrent 5-fluorouracil/mitomycin C and radiotherapy.

105 y to the DNA interstrand cross-linking agent mitomycin C and the topoisomerase-1 inhibitor camptothec

106 t monoubiquitination of PCNA is required for Mitomycin C and Ultraviolet Light inducible SNM1A nuclea

107 heir pretreatment with low concentrations of mitomycin C and vincristine, suggesting that these agent

108 Mitomycin C appears to improve the success rates of EN-D

109 rrence rates of pterygium after surgery with mitomycin C application between the CAU and CLAU groups,

110 c conjunctival resection followed by topical mitomycin C application.

111 cytotoxic antimetabolites, 5-flurouracil and mitomycin C both prolong success but with the increased

112 s have sensitivity to the ICL-inducing agent mitomycin C but do not exhibit chromosome breakage or ce

113 Smoothing agents and intraoperative mitomycin C can be helpful for certain disorders.

114 tivation of mitomycin C with implications in mitomycin C chemotherapy.

115 nchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy significantly imp

116 DNA cross-linking by mitomycin C delayed segregation, and the accumulation of

117 Inhibition of cell proliferation by mitomycin C did not affect the enhancing effect of IL-2

118 Use of conjunctival or limbal autografts or mitomycin C during or after pterygium excision reduced r

119 Mitomycin C enhanced transport of Cx43 from the endoplas

120 llapse caused by methyl methanesulfonate and mitomycin C exposure, a delayed and reduced RAD51 respon

121 s in response to either gamma-irradiation or mitomycin C exposure, two DNA-damaging agents.

122 fected in pol kappa-depleted cells following mitomycin C exposure.

123 ibrovascular tissue and application of 0.02% mitomycin C for 3 minutes.

124 le option for 9/22 (41%) and cryotherapy and Mitomycin C for 6/22 (27%) respondents.

125 PRK enhancement with adjunctive use of Mitomycin C for the correction of residual error of refr

126 temperate phage, PhiHAP-1, was induced with mitomycin C from a Halomonas aquamarina strain isolated

127 ion of conjunctival or limbal autograft with mitomycin C further reduces the recurrence rate after pt

128 Mitomycin C has been shown in studies to be highly effec

129 the mutant strains to UV irradiation and to mitomycin C highlighted the importance of the targeted g

130 PIP-box mutant protein fails to correct the mitomycin C hypersensitivity of FA-D2 patient cells.

131 mutant FANCE protein fails to complement the mitomycin C hypersensitivity of the transfected cells.

132 aled continued production of mitomycin A and mitomycin C in addition to the accumulation of a new mit

133 3 nm solid-state laser (SSL) with adjunctive Mitomycin C in eyes previously treated with laser assist

134 ecreased cellular survival after exposure to mitomycin C in normal fibroblasts depleted for Tip60 ind

135 hough their cells showed mild sensitivity to mitomycin C in terms of cell survival and G(2) phase arr

136 were similar to outcomes for intraoperative mitomycin C in the few studies that directly compared th

137 that RAD51 foci are induced by cisplatin or mitomycin C independently of ERCC1, but that mitomycin C

138 inhibitory concentration of ciprofloxacin or mitomycin C induced sbcDC transcription but repressed th

139 Mitomycin C induces both MC-mono-dG and cross-linked dG-

140 lysogeny proxy determined using DNA-damaging mitomycin C inductions.

141 Subconjunctival mitomycin C injection may cause limbal stem cell deficie

142 B. subtilis is a soil dwelling organism and mitomycin C is a natural antibiotic produced by the soil

143 Mitomycin C is a natural product with potent alkylating

144 n and duration of exposure to intraoperative mitomycin C is associated with increased efficacy.

145 isplatin, 50 mg of doxorubicin, and 10 mg of mitomycin C mixed 1:1 with iodized oil.

146 through replication run off, as we show that mitomycin C or cisplatin-induced DNA lesions are not inc

147 Cultured bovine CE cells were exposed to mitomycin C or other DNA-damaging agents.

148 Exposure of cells to mitomycin C or UV irradiation, but not ionizing radiatio

149 minimal effect on survival after exposure to mitomycin C or UV irradiation.

150 Neither doxorubicin nor mitomycin C potentiated the cytotoxic effects of ischemi

151 Following mitomycin C pretreatment, the stent was placed ab intern

152 Furthermore, we identify that mitomycin C selectively triggers apoptosis in NSCs with

153 ough damage-induced RAD51 foci formation and mitomycin C sensitivity appeared normal in MRG15-binding

154 efects, proliferation capacity reduction and mitomycin C sensitivity equivalent to those produced by

155 epair or prevention of double strand breaks, mitomycin C significantly induces the specific expressio

156 ination and the response of rad23b plants to mitomycin C suggest that RAD23b regulates cell division.

157 erately more sensitive to UV irradiation and mitomycin C than the wild-type strain, the lack of RecA

158 553 mutant strain was much more sensitive to mitomycin C than the WT strain, indicating that HP1553 i

159 lls more sensitive to the crosslinking agent mitomycin C than to ultraviolet radiation, suggesting th

160 oma was higher following trabeculectomy with mitomycin C than tube shunt surgery in the TVT Study.

161 ergistically with very low concentrations of mitomycin C to inhibit proliferation in a WRN-dependent

162 oup antimetabolite analysis, the addition of mitomycin C to TE and DS decreased the difference in the

163 Mitomycin C treatment also protected GJIC from disruptio

164 igG mutant was found to be more resistant to mitomycin C treatment than the wild-type strain, indicat

165 s RecA following methyl methanesulphonate or mitomycin C treatment, but is largely RecA-independent f

166 istant to Triton X extraction in response to mitomycin C treatment.

167 erating cell nuclear antigen irrespective of mitomycin C treatment.

168 nto chromatin following DNA damage caused by mitomycin C treatment.

169 n loading and focus formation in response to mitomycin C treatment.

170 n experimental trabeculectomy surgeries with mitomycin C used as an adjuvant, there were no differenc

171 Of the adjuvants studied, only mitomycin C was associated with vision-threatening compl

172 e single-surgeon comparative study, PRK with mitomycin C was performed to correct hyperopia using Bau

173 acil (FU) plus cisplatin followed by FU plus mitomycin C with concurrent radiation in patients with p

174 tin followed by two 28-day cycles of FU plus mitomycin C with concurrent split-course radiation.

175 vivo role of NQO1 in metabolic activation of mitomycin C with implications in mitomycin C chemotherap

176 Reaction of 9-epi-mitomycin C with MitN in the presence of S-adenosylmethi

177 lowing glaucoma surgery (trabeculectomy with mitomycin C) were included in this institutional study.

178 le ethanol), and an uncompetitive inhibitor (Mitomycin C).

179 primary medical treatments for OSSN include mitomycin C, 5-fluorouracil, and interferon alpha2b.

180 road range of DNA-damaging agents, including mitomycin C, a bifunctional alkylator, etoposide, a topo

181 upon FtsZ depletion and exposure of cells to mitomycin C, a DNA damaging agent, which interferes with

182 y and chromosomal breakage when treated with mitomycin C, a DNA interstrand crosslinker.

183 to be much more sensitive than its parent to mitomycin C, an agent predominantly causing DNA double-s

184 t, intraoperative mitomycin C, postoperative mitomycin C, and amniotic membrane transplantation for p

185 llowed by combined-modality therapy with FU, mitomycin C, and concurrent radiation results in long-te

186 en proliferating IA6+ cells are ablated with Mitomycin C, and injection of a single IA6+ Candidate st

187 persensitivity to the DNA crosslinking agent mitomycin C, and karyotypes feature genomic instability.

188 We revealed that paclitaxel, doxorubicin, mitomycin C, and methotrexate up-regulated the ability o

189 d chemotherapeutic agents: cyclophosphamide, mitomycin C, and procarbazine.

190 ficient tumors were shown to be sensitive to mitomycin C, and the mechanism was presumed to be a defe

191 sensitivity to the DNA cross-linking reagent mitomycin C, and this phenotype can be rescued by comple

192 n and its derivatives, nitrogen mustards and mitomycin C, are used widely in cancer chemotherapy.

193 affects tolerance to the DNA-damaging agent mitomycin C, argue that this prototypic eukaryotic membe

194 ly 4-nitro-o-phenylenediamine, sodium azide, mitomycin C, benzo[a]pyrene, aflatoxin B1 and 2-aminoflu

195 lular resistance to a DNA-crosslinking drug, mitomycin C, but not for the monoubiquitination of FANCD

196 lts in sensitivity to the DNA damaging agent mitomycin C, but not to any other type of DNA damage tes

197 ing the C-terminal bromodomain to X-rays and mitomycin C, but not to other forms of abiotic stress, e

198 These cells were hypersensitive to mitomycin C, but unlike cells defective in other core co

199 terial chemoperfusion was performed by using mitomycin C, cisplatin, and gemcitabine.

200 he exposure of cells to UV irradiation or to mitomycin C, cisplatin, camptothecin, or etoposide, with

201 3B, and Mahlavu)-to ultraviolet irradiation, mitomycin C, doxorubicin, cisplatin, sorafenib, and lapa

202 common use of antineoplastic agents such as mitomycin C, doxorubicin, or oxaliplatin with hypertherm

203 ty of stresses including the genotoxic agent mitomycin C, hydrogen peroxide and at least four differe

204 arious dose levels of three model toxicants, mitomycin C, hydrogen peroxide, and lead nitrate, the an

205 inct but related to the double alkylation by mitomycin C, involving a novel electrophilic spiro-cyclo

206 One member of this family, mitomycin C, is in clinical use as part of combination t

207 tero, microphtalmia, cellular sensitivity to mitomycin C, occasional limb abnormalities and hematolog

208 ms of DNA damage, like exposure to UV light, mitomycin C, or phleomycin, also stimulate Tn7 transposi

209 eatment with DNA-damaging anticancer agents (mitomycin C, oxaliplatin, cisplatin, carboplatin, and a

210 unctival or limbal autograft, intraoperative mitomycin C, postoperative mitomycin C, and amniotic mem

211 n FA-D2(-/-) cells exposed to NSC 617145 and mitomycin C, suggesting that WRN helicase inhibition int

212 ity of cells to the interstrand cross-linker mitomycin C, we found that treatment of cells with HDAC

213 omy achieved comparable surgical outcomes to mitomycin C-augmented combined trabeculotomy-trabeculect

214 ommenced and he underwent a successful right Mitomycin C-augmented trabeculectomy.

215 (+/-) mice also showed limited resistance to mitomycin C-induced bone marrow cytotoxicity.

216 ciated with protection against cisplatin and mitomycin C-induced chromosomal aberrations, and both ar

217 -binding activity and its capacity to rescue mitomycin C-induced cytotoxicity, accounting for two inf

218 Furthermore, mitomycin C-induced DNA double-strand breaks (DSBs) are

219 amage, we analyzed gene expression following mitomycin C-induced genotoxic stress in human E6-express

220 mitomycin C independently of ERCC1, but that mitomycin C-induced HR measured in a reporter construct

221 Here, we report that mitomycin C-induced lesions inhibit replication fork elo

222 , p21(-/-) cells exhibit increased levels of mitomycin C-inducible complex chromosomal aberrations an

223 Mitomycin C-sensitive clones from a transposon mutagenes

224 tion of IFN-gamma production was observed in mitomycin C-treated CD8(+) immune T cells, thus independ

225 tion, and dose and duration of treatment for mitomycin C.

226 and cellular sensitivity to the crosslinker mitomycin C.

227 highly sensitive to the cross-linking agent mitomycin C.

228 rase inhibition, but not DNA crosslinking by mitomycin C.

229 HDAC10 resulted in increased sensitivity to mitomycin C.

230 no influence on sensitivity to cisplatin or mitomycin C.

231 titutively during growth and were induced by mitomycin C.

232 are hypersensitive to the DNA-damaging agent mitomycin C.

233 ypersensitive to the DNA cross-linking agent mitomycin C.

234 following treatment with the genotoxic drug mitomycin C.

235 ion for the production of the clinical agent mitomycin C.

236 and chemicals such as hydrogen peroxide and mitomycin C.

237 a 27% increased survival in the presence of mitomycin C.

238 ce were exposed to five once weekly doses of mitomycin C.

239 ccumulation of a new mitomycin analog, 9-epi-mitomycin C.

240 kinase substrate required for resistance to mitomycin C.

241 ed DPPIV- rats that had been pretreated with mitomycin C.

242 age after treatment with the genotoxic agent mitomycin C.

243 action against noncancer prostate cells over mitomycin C.

244 alternative host and could not be induced by mitomycin C.

245 eater than additive fashion with doxorubicin/mitomycin C/gemcitabine/cisplatin/paclitaxel to cause ce

246 Hg [95% CI, -3.90 to -1.39]; TE and DS with mitomycin C: -0.83 mm Hg [95% CI, -2.40 to 0.74]).

247 e in the reduction in IOP (TE and DS without mitomycin C: -2.65 mm Hg [95% CI, -3.90 to -1.39]; TE an

248 wn to act synergistically with cisplatin and mitomycin C; to increase UVC-mediated cytotoxicity; to m

249 nts who underwent trabeculectomy (Trab) with mitomycin-C (74 eyes of 64 patients) with >/=4 reliable

250 Mitomycin-C (MMC) and balanced saline solution (BSS) tre

251 y aimed to assess the role of intraoperative mitomycin-C (MMC) application during hyperopic LASIK cor

252 gen implant (OLO) versus trabeculectomy plus mitomycin-C (MMC) show contradictory results.

253 s and outcomes of 7 cases of PVOD induced by mitomycin-C (MMC) therapy from the French Pulmonary Hype

254 phacoemulsification and trabeculectomy with mitomycin-C (MMC) vs. Collagen Matrix (CM).

255 ants were capable of fully complementing the mitomycin-C hypersensitivity phenotype of FA-C cells but

256 , smoother stromal beds, and introduction of mitomycin-C intraoperatively have all improved safety ou

257 sed abdomen technique employed cisplatin and mitomycin-C or cisplatin and doxorubicin.

258 ence in intraocular pressure control between mitomycin-C trabeculectomy and nonpenetrating glaucoma s

259 of its perceived superior safety profile to mitomycin-C trabeculectomy.

260 outcome compared to PRK; however, the use of mitomycin-C with PRK has improved results.

261 d a well-known cell proliferation inhibitor (mitomycin-C).

262 Unlike mitomycin-C, neither CCG-222740 nor CCG-203971 caused an

263 non-penetrating glaucoma surgery (NPGS) with mitomycin-C.

264 more sensitive to cytotoxic drugs including Mitomycin, Camptothecin and Cisplatin.

265 , and endophthalmitis, as they relate to the mitomycin concentration administered during the operatio

266 the Kaplan-Meier method, and the relation to mitomycin concentration applied during trabeculectomy.

267 l treatment using instillation of UGN-101, a mitomycin-containing reverse thermal gel.

268 the rate of trabeculectomy complications and mitomycin dose used was P = .77.

269 the presence of S-adenosylmethionine yielded mitomycin E showing that the enzyme functions as an azir

270 esis of a 3-oxo-leucomitosane related to the mitomycin family of alkaloids.

271 391 of 432 (90.5%) patients in the mitomycin group versus 386 of 431 (89.6%) in the cisplat

272 The use of antimetabolite agents, such as mitomycin, has increased the rate of complications after

273 ion of fluorouracil (FU) in combination with mitomycin improves the survival of patients with pancrea

274 SCC received mitomycin in case of tumoral resection margins, respecti

275 not support the use of cisplatin in place of mitomycin in combination with fluorouracil and radiother

276 The cytotoxicity displayed by mitomycins is dependent on their electrochemical potenti

277 more stable N-trityl hemiaminal resemble the mitomycin K substitution pattern.

278 ith ICL agents (cisplatin, camptothecin, and mitomycin), lamin A/C-deficient cells displayed normal g

279 veldt implant (tube) and trabeculectomy with mitomycin may be similarly effective in lowering intraoc

280 d efficacy of KLH were compared with that of mitomycin (MM).

281 oradiation (CCR) with fluorouracil (FU) plus mitomycin (MMC) decreased colostomy failure (CF) when co

282 of tube-shunt surgery to trabeculectomy with mitomycin (MMC) in eyes with previous cataract and/or un

283 three treatment groups: RT/fluorouracil (FU)/mitomycin (n = 472), RT/FU/cisplatin (n = 320), and RT/F

284 of the following after MMED without topical mitomycin: no stenting or packing (group 1, n = 25), 1-w

285 re substitution occurred at C(10) and C(9a) (mitomycin numbering) providing a CD(3) ether and a CD(3)

286 enrolled 940 patients: 472 were assigned to mitomycin, of whom 246 were assigned to no maintenance,

287 minimisation) to receive either intravenous mitomycin (one dose of 12 mg/m(2) on day 1) or intraveno

288 ty-eight patients received fluorouracil (FU)/mitomycin, one received FU/cisplatin, and four received

289 osteochondral defect of the right femur and mitomycin-pretreated apoptotic ADSCs in an osteochondral

290 teins are an adaptation to environments with mitomycin producing bacteria.

291 ehavior of typical aziridinomitosenes in the mitomycin series.

292 4.8 years, and all patients had a history of mitomycin use at the time of glaucoma surgery.

293 ations does not appear to be associated with mitomycin use during a mean follow-up of 7.7 years.

294 ere similar in each group (334/472 [71%] for mitomycin vs 337/468 [72%] for cisplatin).

295 he cost-effectiveness of trabeculectomy with mitomycin vs tube insertion.

296 However, mitomycin was performed in 93.3% and 20.5% of miSCC and

297 l cancer to date--show that fluorouracil and mitomycin with 50.4 Gy radiotherapy in 28 daily fraction

298 We investigated whether replacing mitomycin with cisplatin in chemoradiation improves resp

299 synthetic pathway leading to the subclass of mitomycins with 9alpha-stereochemistry but is not involv

300 have been found to be similar in efficacy to mitomycin, with interferon being extremely well tolerate